| HBT | human brain thromboplastin; human breast tumor |
|---|---|
| HCS | Hajdu-Cheney syndrome; Hazard Communication Standard; health care support; hourglass contraction of ... |
| hCT | human calcitonin; human chorionic thyrotropin |
| HEK | human embryo kinase; human embryonic kidney |
| HEL | hen egg white lysozyme; human embryonic lung; human erythroleukemia |
| hepatitis B surface antigen | <virology> A serologic marker on the surface of the hepatitis B virus. The body will normally produce antibodies to hepatitis B surface antigen as part of the normal immune response to infection. It is the presence of antibodies to the hepatitis B surface antigen that are detected in a positive hepatitis B blood test. (27 Sep 1997) |
|---|---|
| hepatitis b surface antigens | Those hepatitis b antigens found on the surface of the dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. (12 Dec 1998) |
| hepatitis B vaccine | <virology> An injectable vaccine, given in three boosters, which offers protection from infection with hepatitis B. (27 Sep 1997) |
| hepatitis b vaccines | Vaccines or candidate vaccines containing inactivated hepatitis b or some of its component antigens and designed to prevent hepatitis b. Some vaccines may be recombinantly produced. (12 Dec 1998) |
| hepatitis C | <virology> A form of viral hepatitis, previously referred to as nonA nonB hepatitis, is the most common form of blood transfusion acquired hepatitis. Transmission through sexual contact is considered rare. Risk factors include recent blood transfusion, IV drug abuse or occupational exposure to blood products. There is no specific treatment. There is a test for hepatitis C antibody which indicates prior exposure. Unlike hepatitis b there is no marker yet identifiable for those who suffer from chronic hepatitis C. (27 Sep 1997) |
| hepatitis c antibodies | Antibodies to the hepatitis c antigens including antibodies to envelope, core, and non-structural proteins. (12 Dec 1998) |
| hepatitis c antigens | Antigens of the virions of hepatitis c-like viruses, their surface, core, or other associated antigens. (12 Dec 1998) |
| hepatitis c, chronic | An inflammatory disease of the liver caused by hepatitis c virus lasting six months or more. (12 Dec 1998) |
| hepatitis, chronic | A collective term for a clinical and pathological syndrome which has several causes and is characterised by varying degrees of hepatocellular necrosis and inflammation. Specific forms of chronic hepatitis include autoimmune hepatitis (hepatitis, autoimmune), chronic hepatitis b (hepatitis b, chronic), chronic hepatitis c (hepatitis c, chronic), chronic hepatitis d (hepatitis d, chronic), indeterminate chronic viral hepatitis, cryptogenic chronic hepatitis and drug-related chronic hepatitis (hepatitis, chronic, drug-induced). (12 Dec 1998) |
| hepatitis, chronic, drug-induced | An inflammatory disease of the liver, lasting six months or more, and caused by an adverse drug effect. The adverse effect may result from a direct toxic effect of a drug or metabolite, or an idiosyncratic response to a drug or metabolite. The clinical and histological changes can mimic viral or autoimmune hepatitis. (12 Dec 1998) |
| hepatitis c-like viruses | A genus of flaviviridae causing parenterally-transmitted non-a, non-b hepatitis (hepatitis c) which is associated with transfusions and drug abuse. Hepatitis c virus is the type species. (12 Dec 1998) |
| hepatitis contagiosa canis | A disease of dogs, caused by canine adenovirus 1, and characterised by fever, depression, loss of appetite, vomiting, bloody diarrhoea, petechial haemorrhages in the gums, pale mucous membranes, and jaundice. Synonym: hepatitis contagiosa canis, Rubarth's disease. (05 Mar 2000) |
| hepatitis D | <virology> A rare form of viral transfusion hepatitis. A defective viral agent that occurs only in association with hepatitis B infection. The delta agent may also increase the severity of hepatitis B infection. Complications include chronic persistent hepatitis and fulminant hepatitis. A test known as anti-delta agent antibody is positive and used to confirm the diagnosis. Treatment is the same as for hepatitis B. (27 Sep 1997) |
| hepatitis d, chronic | Inflammatory disease of the liver caused by hepatitis d virus in conjunction with hepatitis b virus and lasting six months or more. (12 Dec 1998) |
| hepatitis d, e, f, and g | Lesser known (than hepatitis a, b, and c), the most significant of these seems to be type d, or the delta agent, which only causes disease in the presence of the hepatitis b virus. (12 Dec 1998) |